Cargando…
Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study
BACKGROUND: This study was designed to evaluate the efficacy and safety of fulranumab, a fully human monoclonal antibody directed against nerve growth factor (NGF), for pain relief in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). METHODS: In this multicenter, double-blind study...
Autores principales: | Wang, Hao, Russell, Lucille J., Kelly, Kathleen M., Wang, Steven, Thipphawong, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217311/ https://www.ncbi.nlm.nih.gov/pubmed/28056917 http://dx.doi.org/10.1186/s12894-016-0193-z |
Ejemplares similares
-
Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study
por: Wang, Hao, et al.
Publicado: (2017) -
Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
por: Kasyan, George, et al.
Publicado: (2021) -
The Overlap of Interstitial Cystitis/Painful Bladder Syndrome and Overactive Bladder
por: Chung, Maurice K., et al.
Publicado: (2010) -
Increased bladder permeability in interstitial cystitis/painful bladder syndrome
por: Hurst, Robert E., et al.
Publicado: (2015) -
Stool-based biomarkers of interstitial cystitis/bladder pain syndrome
por: Braundmeier-Fleming, A., et al.
Publicado: (2016)